Sign Up to like & get
recommendations!
1
Published in 2020 at "Current Opinion in Allergy and Clinical Immunology"
DOI: 10.1097/aci.0000000000000623
Abstract: PURPOSE OF REVIEW Severe asthma remains a debilitating disease and a challenge for the clinicians. Novel therapies have been introduced and have greatly improved asthma control and more are under development or in clinical studies.…
read more here.
Keywords:
severe asthma;
asthma new;
asthma;
new new ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "ERJ Open Research"
DOI: 10.1183/23120541.00309-2020
Abstract: Currently, and based on the development of relevant biologic therapies, T2-high is the most well-defined endotype of asthma. Although much progress has been made in elucidating T2-high inflammation pathways, no specific clinically applicable biomarkers for…
read more here.
Keywords:
inflammation;
biologic agents;
low asthma;
treatment low ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2023 at "Frontiers in Genetics"
DOI: 10.3389/fgene.2023.1186317
Abstract: Background: Type 2 (T2)-low asthma can be severe and corticosteroid-resistant. Airway epithelial cells play a pivotal role in the development of asthma, and mitochondria dysfunction is involved in the pathogenesis of asthma. However, the role…
read more here.
Keywords:
airway epithelial;
asthma;
low asthma;
degs ... See more keywords
Sign Up to like & get
recommendations!
3
Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2023.1107031
Abstract: Introduction Asthma is primarily divided into two categories: type 2 (T2-high) and non-type 2 (T2-low). A relationship between asthma severity and vitamin D deficiency has been identified, but its impact on each asthma endotype remains…
read more here.
Keywords:
effects vitamin;
airway obstruction;
asthma endotypes;
asthma ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Biomedicines"
DOI: 10.3390/biomedicines11041226
Abstract: Asthma affects 10% of the worldwide population; about 5% of cases are severe with the need for target therapies such as biologics. All the biologics approved for asthma hit the T2 pathway of inflammation. T2-high…
read more here.
Keywords:
asthma;
discussed still;
low asthma;
orphan disease ... See more keywords